High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment

Chronic immune activation is a driver of human immunodeficiency virus type 1 (HIV-1) disease progression. Here, we describe that subjects with chronic hepatitis C virus (HCV)/HIV-1 coinfection display sharply elevated immune activation as determined by CD38 expression in T cells. This occurs, despit...

Full description

Saved in:
Bibliographic Details
Published in:Journal of virology Vol. 83; no. 21; p. 11407
Main Authors: Gonzalez, Veronica D, Falconer, Karolin, Blom, Kim G, Reichard, Olle, Mørn, Birgitte, Laursen, Alex Lund, Weis, Nina, Alaeus, Annette, Sandberg, Johan K
Format: Journal Article
Language:English
Published: United States 01.11.2009
Subjects:
ISSN:1098-5514, 1098-5514
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Chronic immune activation is a driver of human immunodeficiency virus type 1 (HIV-1) disease progression. Here, we describe that subjects with chronic hepatitis C virus (HCV)/HIV-1 coinfection display sharply elevated immune activation as determined by CD38 expression in T cells. This occurs, despite effective antiretroviral therapy, in both CD8 and CD4 T cells and is more pronounced than in the appropriate monoinfected control groups. Interestingly, the suppression of HCV by pegylated alpha interferon and ribavirin treatment reduces activation. High HCV loads and elevated levels of chronic immune activation may contribute to the high rates of viral disease progression observed in HCV/HIV-1-coinfected patients.
AbstractList Chronic immune activation is a driver of human immunodeficiency virus type 1 (HIV-1) disease progression. Here, we describe that subjects with chronic hepatitis C virus (HCV)/HIV-1 coinfection display sharply elevated immune activation as determined by CD38 expression in T cells. This occurs, despite effective antiretroviral therapy, in both CD8 and CD4 T cells and is more pronounced than in the appropriate monoinfected control groups. Interestingly, the suppression of HCV by pegylated alpha interferon and ribavirin treatment reduces activation. High HCV loads and elevated levels of chronic immune activation may contribute to the high rates of viral disease progression observed in HCV/HIV-1-coinfected patients.Chronic immune activation is a driver of human immunodeficiency virus type 1 (HIV-1) disease progression. Here, we describe that subjects with chronic hepatitis C virus (HCV)/HIV-1 coinfection display sharply elevated immune activation as determined by CD38 expression in T cells. This occurs, despite effective antiretroviral therapy, in both CD8 and CD4 T cells and is more pronounced than in the appropriate monoinfected control groups. Interestingly, the suppression of HCV by pegylated alpha interferon and ribavirin treatment reduces activation. High HCV loads and elevated levels of chronic immune activation may contribute to the high rates of viral disease progression observed in HCV/HIV-1-coinfected patients.
Chronic immune activation is a driver of human immunodeficiency virus type 1 (HIV-1) disease progression. Here, we describe that subjects with chronic hepatitis C virus (HCV)/HIV-1 coinfection display sharply elevated immune activation as determined by CD38 expression in T cells. This occurs, despite effective antiretroviral therapy, in both CD8 and CD4 T cells and is more pronounced than in the appropriate monoinfected control groups. Interestingly, the suppression of HCV by pegylated alpha interferon and ribavirin treatment reduces activation. High HCV loads and elevated levels of chronic immune activation may contribute to the high rates of viral disease progression observed in HCV/HIV-1-coinfected patients.
Author Weis, Nina
Mørn, Birgitte
Laursen, Alex Lund
Falconer, Karolin
Reichard, Olle
Alaeus, Annette
Blom, Kim G
Sandberg, Johan K
Gonzalez, Veronica D
Author_xml – sequence: 1
  givenname: Veronica D
  surname: Gonzalez
  fullname: Gonzalez, Veronica D
  organization: Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden
– sequence: 2
  givenname: Karolin
  surname: Falconer
  fullname: Falconer, Karolin
– sequence: 3
  givenname: Kim G
  surname: Blom
  fullname: Blom, Kim G
– sequence: 4
  givenname: Olle
  surname: Reichard
  fullname: Reichard, Olle
– sequence: 5
  givenname: Birgitte
  surname: Mørn
  fullname: Mørn, Birgitte
– sequence: 6
  givenname: Alex Lund
  surname: Laursen
  fullname: Laursen, Alex Lund
– sequence: 7
  givenname: Nina
  surname: Weis
  fullname: Weis, Nina
– sequence: 8
  givenname: Annette
  surname: Alaeus
  fullname: Alaeus, Annette
– sequence: 9
  givenname: Johan K
  surname: Sandberg
  fullname: Sandberg, Johan K
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19710147$$D View this record in MEDLINE/PubMed
BookMark eNpNUU1v1DAQtVAR_YAbZzQ3Til2nC8f0Qpoq0pcCteV7YyJUWIH29lq_zzCyS5ST57RvDfvvfE1uXDeISHvGb1lrOw-Pfy8v6WsZKyg4hW5YlR0RV2z6uJFfUmuY_xNKauqpnpDLploWW7aK_L3zv4aYMQDjhG8AT0E76wGO02LQ5A62YNM1juwDtKA8FRoHEfQfpplSBO6tPHmDNpq7a0zqBP28GzTAAOuo2Qj7OBgwxJBuh6GZZLuJOJ7NFZnsj6eAek4I7ANl3WHbHA8npxkQy7ZgCn4DJXj6ijIOU8DQsghwqqrcj_Og8yWEwaDOdG2LFglM20NElBu3t-S10aOEd-d3xvy4-uXp91d8fj92_3u82Ohq1akAmvFpFG84W3DeM85GmG4YqYVjSyRd7wXStOubajimjdKClVRozrUtRAGyxvy8bR3Dv7PgjHtJxvXQ0qHfon7lnNR1R1tMvLDGbmoCfv9HOwkw3H__8vKf0_TojE
CitedBy_id crossref_primary_10_1186_s12981_021_00330_6
crossref_primary_10_1016_j_drugalcdep_2017_07_023
crossref_primary_10_1016_j_actatropica_2017_05_011
crossref_primary_10_1016_j_jinf_2023_03_011
crossref_primary_10_3389_fimmu_2023_1146791
crossref_primary_10_1016_j_virol_2012_04_011
crossref_primary_10_1186_1471_2334_10_358
crossref_primary_10_1097_QAI_0b013e318289439a
crossref_primary_10_1097_QAD_0b013e32835ecb8b
crossref_primary_10_1111_liv_12363
crossref_primary_10_1002_jmv_24419
crossref_primary_10_1111_jvh_13818
crossref_primary_10_1128_CMR_00050_12
crossref_primary_10_1093_infdis_jit135
crossref_primary_10_14283_jfa_2021_44
crossref_primary_10_1016_j_clim_2009_12_005
crossref_primary_10_1097_QAI_0000000000001157
crossref_primary_10_1089_aid_2014_0299
crossref_primary_10_4081_idr_2017_7142
crossref_primary_10_5812_hepatmon_4908
crossref_primary_10_1111_hiv_13680
crossref_primary_10_1097_INF_0000000000001478
crossref_primary_10_1124_dmd_115_067827
crossref_primary_10_1097_MD_0000000000012238
crossref_primary_10_1007_s11904_010_0071_3
crossref_primary_10_1097_01_aids_0000432470_46379_dd
crossref_primary_10_1093_jac_dkq518
crossref_primary_10_1371_journal_pone_0018779
crossref_primary_10_1007_s40265_016_0546_7
crossref_primary_10_1155_2020_2781350
crossref_primary_10_1371_journal_pone_0101441
crossref_primary_10_1371_journal_pone_0173943
crossref_primary_10_1007_s12072_019_09941_8
crossref_primary_10_1016_j_ebiom_2016_05_008
crossref_primary_10_1111_apm_12429
crossref_primary_10_1097_QAI_0000000000001940
crossref_primary_10_1097_MD_0000000000004483
crossref_primary_10_1186_s12879_017_2942_3
crossref_primary_10_1097_QAD_0b013e328357f5d1
crossref_primary_10_1016_j_chom_2009_10_010
crossref_primary_10_1093_infdis_jiae598
crossref_primary_10_1093_ofid_ofab079
crossref_primary_10_2217_fvl_11_80
crossref_primary_10_1093_ofid_ofaa383
crossref_primary_10_1111_jvh_12226
crossref_primary_10_1016_j_jcv_2016_05_019
crossref_primary_10_1111_jvh_12101
crossref_primary_10_1016_j_smim_2021_101471
crossref_primary_10_1002_iid3_70138
crossref_primary_10_3389_fped_2023_1308700
crossref_primary_10_1097_QAD_0000000000003739
crossref_primary_10_1097_QAD_0b013e32833adbb5
crossref_primary_10_1080_2162402X_2015_1128612
crossref_primary_10_1097_QAI_0000000000000310
crossref_primary_10_1111_sji_12429
crossref_primary_10_1371_journal_pone_0059302
crossref_primary_10_1111_hiv_13218
crossref_primary_10_1016_S0140_6736_13_61809_7
crossref_primary_10_1016_j_medmal_2018_07_005
crossref_primary_10_1186_1742_6405_10_29
crossref_primary_10_1097_COH_0000000000000072
crossref_primary_10_1097_QAD_0b013e328362dea4
crossref_primary_10_1089_aid_2010_0107
crossref_primary_10_1155_2012_670957
crossref_primary_10_1093_ofid_ofu104
crossref_primary_10_1002_jmv_29515
crossref_primary_10_1182_blood_2010_12_322453
crossref_primary_10_1097_QAD_0000000000001455
crossref_primary_10_1186_s12977_018_0390_9
crossref_primary_10_1097_COH_0000000000000118
crossref_primary_10_1111_hiv_12310
crossref_primary_10_1016_j_clinre_2017_11_006
crossref_primary_10_1097_QAI_0b013e31829c6de0
crossref_primary_10_1002_JLB_4MR1019_189R
crossref_primary_10_3390_jcm9092978
crossref_primary_10_1016_j_epidem_2015_04_001
crossref_primary_10_1097_QAD_0000000000001109
crossref_primary_10_1002_jmv_24475
crossref_primary_10_1371_journal_pone_0203272
crossref_primary_10_1097_QAD_0000000000000650
crossref_primary_10_1007_s15010_017_1093_1
crossref_primary_10_1371_journal_pone_0032028
crossref_primary_10_1134_S0012496616040062
crossref_primary_10_1186_s12981_016_0105_z
crossref_primary_10_3390_biomedicines10040768
crossref_primary_10_1089_apc_2015_0040
crossref_primary_10_1155_2012_515962
crossref_primary_10_3390_diagnostics11122336
crossref_primary_10_1155_2013_176459
crossref_primary_10_1111_ijcp_12066
crossref_primary_10_1089_vim_2021_0027
crossref_primary_10_1371_journal_pone_0055776
crossref_primary_10_1007_s00430_019_00619_4
crossref_primary_10_1089_aid_2011_0318
crossref_primary_10_1111_apm_12561
crossref_primary_10_1016_j_carrev_2010_11_006
crossref_primary_10_1016_S0140_6736_14_60164_1
crossref_primary_10_1089_aid_2011_0323
crossref_primary_10_1111_jvh_12714
crossref_primary_10_3109_00365548_2010_498019
crossref_primary_10_1093_infdis_jit402
crossref_primary_10_1016_j_eimce_2017_02_011
crossref_primary_10_1093_carcin_bgy149
crossref_primary_10_1111_jvh_13488
crossref_primary_10_1089_aid_2014_0284
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1128/JVI.01211-09
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Biology
EISSN 1098-5514
ExternalDocumentID 19710147
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
.GJ
0R~
18M
29L
2WC
39C
3O-
4.4
41~
53G
5GY
5RE
5VS
6TJ
85S
AAYJJ
ABPPZ
ACGFO
ACNCT
ADBBV
AENEX
AFFNX
AGVNZ
AI.
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CGR
CS3
CUY
CVF
D0S
DIK
E3Z
EBS
ECM
EIF
EJD
F5P
FRP
GX1
H13
HYE
HZ~
IH2
KQ8
MVM
N9A
NPM
O9-
OHT
OK1
P2P
RHI
RNS
RPM
RSF
TR2
UPT
VH1
W2D
W8F
WH7
WOQ
X7M
Y6R
YQT
ZGI
ZXP
~02
~KM
7X8
AAFWJ
AAGFI
ID FETCH-LOGICAL-c479t-e5b1afb3637613d33ef9f3b1f796a2e383d9bc08760b3c36ba9b40fb8ec599fe2
IEDL.DBID 7X8
ISICitedReferencesCount 118
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000270602300055&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1098-5514
IngestDate Thu Sep 04 19:06:41 EDT 2025
Thu Apr 03 07:03:35 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 21
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c479t-e5b1afb3637613d33ef9f3b1f796a2e383d9bc08760b3c36ba9b40fb8ec599fe2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://jvi.asm.org/content/jvi/83/21/11407.full.pdf
PMID 19710147
PQID 733945806
PQPubID 23479
ParticipantIDs proquest_miscellaneous_733945806
pubmed_primary_19710147
PublicationCentury 2000
PublicationDate 2009-11-01
PublicationDateYYYYMMDD 2009-11-01
PublicationDate_xml – month: 11
  year: 2009
  text: 2009-11-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of virology
PublicationTitleAlternate J Virol
PublicationYear 2009
SSID ssj0014464
Score 2.3503358
Snippet Chronic immune activation is a driver of human immunodeficiency virus type 1 (HIV-1) disease progression. Here, we describe that subjects with chronic...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 11407
SubjectTerms ADP-ribosyl Cyclase 1 - immunology
Adult
Antiretroviral Therapy, Highly Active
Antiviral Agents - therapeutic use
Disease Progression
Female
Hepacivirus - immunology
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - immunology
Hepatitis C, Chronic - virology
HIV Infections - drug therapy
HIV Infections - immunology
HIV Infections - virology
HIV-1 - immunology
Humans
Interferon-alpha - immunology
Interferon-alpha - therapeutic use
Lymphocyte Activation - immunology
Male
Middle Aged
Ribavirin - therapeutic use
T-Lymphocyte Subsets - immunology
T-Lymphocyte Subsets - virology
T-Lymphocytes - immunology
T-Lymphocytes - virology
Viral Load
Young Adult
Title High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment
URI https://www.ncbi.nlm.nih.gov/pubmed/19710147
https://www.proquest.com/docview/733945806
Volume 83
WOSCitedRecordID wos000270602300055&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwELUotBIXSj9ogYLm0KtLEmfj-FRVCNQiseJAq72t7HisRkIJTRYk_jzqjJ1tb_TQS6TIdmzHk8l4_OaNEB-V9kVwTklX1JWk_20pazcrJWaNdcqzDPmYbELP5_ViYa4mbM44wSrXOjEqat837CM_0UqZclZn1efbX5KTRvHh6pRB45nYUmTJsFDrxd9DBNrpxENlpsxkw2CNey_qk4sf3z5FdjOZPWFbxn_M-cv_HN2u2JmMS_iSpOGV2MDutXiR0k0-vBGPDOqAG4YJjdAHaBIxLrQcI4LAIQ7JQQttB2QYwrVkvz4knHqEo8d2ExfrSAUJy4Ue2J8LP5GLVu0Ip3DfDncj2M5DTAOYOuk9MmMFh3tOFdgFDHmsR_0yefLNQxoJDahbkUJesdNjoGmlUDEqHRCYeGrgfh3dc7gwMO_FEJBmFB82tM5SM57IGkr_Vnw_P7s-_Sqn_A-yKbVZSZy53AanKlKCufJKYTBBuTxoU9kCaW_tjWuYUy9zqlGVs8aVWXA1NjNjAhZ7YrPrO3wvINeB9n2lxaL0JYkgp1gm44_sH5vXIbh9Aet1XdL3xS_Xdtjfjcs_K7sv3iXZWN4mHpBlbjRnOtYH_258KLbjMVQMYvwgtgLpFjwSz5t7WpPhOMotXedXl78BEGn_3A
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High+levels+of+chronic+immune+activation+in+the+T-cell+compartments+of+patients+coinfected+with+hepatitis+C+virus+and+human+immunodeficiency+virus+type+1+and+on+highly+active+antiretroviral+therapy+are+reverted+by+alpha+interferon+and+ribavirin+treatment&rft.jtitle=Journal+of+virology&rft.au=Gonzalez%2C+Veronica+D&rft.au=Falconer%2C+Karolin&rft.au=Blom%2C+Kim+G&rft.au=Reichard%2C+Olle&rft.date=2009-11-01&rft.eissn=1098-5514&rft.volume=83&rft.issue=21&rft.spage=11407&rft_id=info:doi/10.1128%2FJVI.01211-09&rft_id=info%3Apmid%2F19710147&rft_id=info%3Apmid%2F19710147&rft.externalDocID=19710147
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-5514&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-5514&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-5514&client=summon